


Golotimod

Cat. No.:	HY-14743
CAS No.:	229305-39-9
Molecular Formula:	C ₁₆ H ₁₉ N ₃ O ₅
Molecular Weight:	333.34
Target:	Bacterial; STAT
Pathway:	Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) ^{[1][2][3]} .
IC₅₀ & Target	STAT3

REFERENCES

- [1]. Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). *Int J Antimicrob Agents*. 2008 Sep;32(3):262-6.
- [2]. Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. *Oral Oncol*. 2016 May;56:84-92.
- [3]. Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). *Oral Dis*. 2010 Oct;16(7):655-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA